No Data
Fulcrum Therapeutics to Participate in Upcoming May Conferences
Oppenheimer Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Cuts Target Price to $12
RBC Capital Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Piper Sandler Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $6
Piper Sandler Sticks to Its Buy Rating for Fulcrum Therapeutics (FULC)
Q1 2025 Fulcrum Therapeutics Inc Earnings Call